#Oncology #ClinicalTrials
https://thepriorityreview.com/news/epcoritamab-china-dlbcl-median-overall-survival-7-7-vs-9-0-months
#Oncology #ClinicalTrials
https://thepriorityreview.com/news/epcoritamab-china-dlbcl-median-overall-survival-7-7-vs-9-0-months
Genmab grew nine month revenue 22 percent to 3.238 billion dollars as DARZALEX royalties and a 47 percent jump in EPKINLY sales offset flat operating profit, and it kept full year guidance in place.
Genmab grew nine month revenue 22 percent to 3.238 billion dollars as DARZALEX royalties and a 47 percent jump in EPKINLY sales offset flat operating profit, and it kept full year guidance in place.
https://www.merlintrader.com/genmab-gmab-stock-hub/
https://www.merlintrader.com/genmab-gmab-stock-hub/
https://justcharts.merlintrader.com/?utm_source=bluesky&utm_medium=social&utm_campaign=jc20261107&utm_content=GMAB#GMAB
Visit Justcharts for bull/bear scenarios.
$53.63, +1.7%. RSI 71.
https://justcharts.merlintrader.com/?utm_source=bluesky&utm_medium=social&utm_campaign=jc20261107&utm_content=GMAB#GMAB
Visit Justcharts for bull/bear scenarios.
$53.63, +1.7%. RSI 71.
#$GMAB FAQ + PDF report: www.merlintrader.com/genmab-gmab-...
#$GMAB FAQ + PDF report: www.merlintrader.com/genmab-gmab-...
https://fundspec.ai/s/GMAB/earnings
Every headline that matters for your tickers, in one feed.
https://fundspec.ai/s/GMAB/earnings
Every headline that matters for your tickers, in one feed.
🇩🇰 #$GMAB Q3 revenue $1,187m, +16%: Epkinly own sales +43%, Darzalex royalties +14%. Profit before tax −27%: R&D +$97m, loan interest $82m. Net −15% at a 3.4% tax rate that Genmab calls not indicative. Guidance kept.
midgardfinance.com/companies/GMAB.CO/
🇩🇰 #$GMAB Q3 revenue $1,187m, +16%: Epkinly own sales +43%, Darzalex royalties +14%. Profit before tax −27%: R&D +$97m, loan interest $82m. Net −15% at a 3.4% tax rate that Genmab calls not indicative. Guidance kept.
midgardfinance.com/companies/GMAB.CO/
🇩🇰 #$GMAB Q3-omsætning 1.187 mio. $, +16%: Epkinlys eget salg +43%, Darzalex-royalties +14%. Før skat −27%: F&U +97 mio. $, lånerenter 82 mio. $. Netto −15% ved 3,4% skattesats, ikke retningsgivende ifølge Genmab. Guidance uændret.
midgardfinance.com/companies/GMAB.CO/
🇩🇰 #$GMAB Q3-omsætning 1.187 mio. $, +16%: Epkinlys eget salg +43%, Darzalex-royalties +14%. Før skat −27%: F&U +97 mio. $, lånerenter 82 mio. $. Netto −15% ved 3,4% skattesats, ikke retningsgivende ifølge Genmab. Guidance uændret.
midgardfinance.com/companies/GMAB.CO/
Focus - Yahoo Finance >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #biotech #pharmaceutical
Focus - Yahoo Finance >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #biotech #pharmaceutical
#NewsBrief #FINews
#NewsBrief #FINews